NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-NS-22-052 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the proposal must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, obstetric pain, gynecologic pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered.
Notice NOT-AA-22-013 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-110 from the NIH Guide for Grants and Contracts
Notice NOT-DK-22-021 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-116 from the NIH Guide for Grants and Contracts
Notice NOT-MD-22-017 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-23-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for three-year demonstration projects to study the feasibility of, and develop best practices for, using interoperable health information from older adult research participants. Applicants will partner with one or more actively funded research studies that are enrolling or re-consenting older adult participants. The projects are expected to collect medical information from electronic health records (EHRs) shared by participants, combine the information inside of a digital infrastructure, and create approaches to harmonize the data across patients and providers. The projects should also develop approaches to analyze health conditions prevalent in older adults in the harmonized medical data through informatic methods, such as natural language processing. Proposals should consider the potential impact of the project on the outcomes of the partner study, as well as broader impacts overall.
Funding Opportunity PAR-22-152 from the NIH Guide for Grants and Contracts. The Fogarty HIV Research Training Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program.These applications must propose a plan to develop a research training program and the subsequent application that will be submitted in response to the companion D43 FOA (PAR-19-283). The planned research training program should strengthen research capacity in a defined high priority HIV scientific area (NOT-OD-15-137) at an LMIC institution(s).
Funding Opportunity PAR-22-153 from the NIH Guide for Grants and Contracts. The overall goal of the Fogarty International Center (FIC) HIV Research Training Program is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research on the evolving HIV epidemic in their countries.This FOA encourages collaborative applications from U.S. and LMIC institutions to support training to achieve technical, administration and financial management expertise required for one of the six research infrastructure functions considered critical to a successful high quality research environment:Research administration and management;Research integrity oversight;Ethical review of research for the protection of human subjects;Laboratory animal welfare oversightHealth sciences library and information services; andInformation and communications technology systems (ICT) for researchResearch infrastructure training programs will maximize previous investments and further strengthen the LMIC institution's research capabilities, and provide more accessible research infrastructure training opportunities to others in their own country and in other LMICs.
Funding Opportunity PAR-22-151 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA can support training for conducting research in a broad range of HIV research areas across HIV prevention, treatment, care, and quality of life continuum. This includes basic, epidemiologic, clinical, behavioral and social sciences, community-based, implementation, operations, health services, and health systems research. Cross-disciplinary research as well as HIV associated comorbidities and coinfections affecting the HIV epidemic will be supported under this FOA. An application should focus the proposed training program to strengthen research capacity in a defined high priority HIV scientific area aligned with NIH HIV/AIDS research priorities (NOT-OD-20-018) at a specific LMIC institution and collaborating LMIC partner institutions.
Notice NOT-CA-22-082 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-115 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-114 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-166 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for support of mature structural biology resources at synchrotron facilities. Mature refers to the techniques made available at the resource beamlines: they must be well-established, requiring no significant novel technology development in order to provide utility to the communities they serve or to maintain them as state-of-the-art beamlines. This funding opportunity is limited to resources whose operations recently have been or currently are being supported by NIGMS funding. The intent is to provide access to X-ray beamlines for structural biology research. It is expected that the facility will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support
Funding Opportunity PAR-22-163 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for NIH individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH. The goal of this FOA is to support existing COBRE Phase 1 Centers by further strengthening the research infrastructure and to continue the development and support of a critical mass of investigators with the expertise in the Center's scientific interest areas.
Funding Opportunity RFA-AG-23-028 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to define and characterize neuronal and glial cell populations that are vulnerable to Alzheimer's disease (AD) and AD-related dementias (ADRD) proteinopathies.
Notice NOT-MD-22-016 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-003 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-142 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may include Phase 1 and 2 studies of drugs and biologics, feasibility studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All exploratory trials must contribute to the justification for and provide some of the data required to inform a future trial to establish efficacy (such as a Phase 3, Phase 4 or Pivotal trial). This FOA uses the UG3/UH3 mechanism. Only projects that provide satisfactory progress in the UG3 phase may move to the UH3 phase, as outlined below. For a drug, biologic or device that has not completed a Phase 1/Early Feasibility trial: The UG3 mechanism will be used to plan and execute the Phase I trial(s). If Phase 1 trials are successful, the UG3 will also include the planning phase of a Phase 2 trial. The UH3 mechanism will then support the execution of the Phase 2 clinical trial. Transition to the UH3 will depend on successfully reaching agreed upon milestones. For a drug, biologic or device that has successfully completed the Phase 1/Early Feasibility trial(s), do not use this FOA. Instead use the Companion FOA XXX. For genetic studies, do not use this FOA. Instead, use FOA XXX.
Notice NOT-CA-22-081 from the NIH Guide for Grants and Contracts